Vancomycin Dextrose Injectable Recalled Due to Sterility Concerns
Central Admixture Pharmacy Services is recalling 13,772 bags of vancomycin-dextrose injectable distributed nationwide after an FDA inspection questioned its sterility assurance. No illnesses have been reported.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. The hazard is theoretical—an FDA inspection questioned sterility assurance—but actual contamination or patient harm has not been documented. This meets the High criterion for risk-of-harm products without reported injury.
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling vancomycin added to dextrose 5% (1.25 g/250 mL per 250 mL bag) distributed nationwide. The recall affects 13,772 bags across multiple lot numbers, with expiration dates ranging from April 30 to June 7, 2023.
The FDA inspection called into question whether these products maintain their sterile status. Because vancomycin-dextrose is administered intravenously and is required to be sterile, any loss of sterility assurance poses a risk of infection to patients who receive the product.
Healthcare providers and pharmacies should not use any product with the affected lot numbers. Patients who received this medication should contact their healthcare provider to discuss their exposure. No illnesses or injuries have been reported to date.
The recalled product
- Product
- vancomycin added to dextrose 5%, 1.25 g/250 mL* (5 mg/mL), 250 mL per bag, Rx only, Central Admixture Pharmacy Services, Inc., 6580 Snowdrift Rd., Ste 100, Allentown, PA 18106, NDC 71285-6073-1.
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Hazard
- sterility-assurance
- contamination-risk
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot # 37-883198
- 37-883202
- 37-883203
- 37-883204
- Exp 04/30/2023
- 37-883799
- Exp 05/02/2023
- 37-884159
- Exp 05/03/2023
- 37-884888
- 37-884892
- 37-884899
- 37-884901
- Exp 05/07/2023
- 37-886836
- 37-886855
- 37-886861
- Exp 05/15/2023
- 37-887381
- Exp 05/16/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27